Delix Therapeutics is an American biotech company based in Boston, Massachusetts.[1][2] The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD).[3][2] It was co-founded in 2019 by David E. Olson and Nick Haft.[4][2]
The company was founded to develop novel, non-hallucinogenic
In 2021, Delix was named one of the Fierce 15 of Biotech.[7] In 2022, Nature named Delix Spinout of the Year[8] and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award.[9] In 2023, Delix was a finalist for the Prix Galien award for Best Startup[10] and the BWB award for Biotech Innovation of the Year[11] and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year.[12]
To date, the company has synthesized over 2,000 novel psychoplastogens.[13] Many of these small molecule compounds are analogs of known psychedelics such as ibogaine and 5-MeO-DMT.[14] Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.[15] Their compounds have been engineered to lack cardiotoxicity and psychostimulant properties characteristic of other first-generation psychoplastogens.[16] The company’s known drug candidates include zalsupindole (DLX-001; AAZ-A-154), tabernanthalog (DLX-007), and DLX-159.[17][18] Delix has licensed these compounds from UC Davis.[19]
